Comparative clinical significance and biological roles of PFKFB family members in oral squamous cell carcinoma

Table 4 The association of PFKFB4 expression with prognosis in oral cancer patients stratified by different clinicopathological features

PFKFB4	ROC	OS			PFI			DFI			DSS
PFKFB4	ROC	No	AHR	p	No	AHR	p	No	AHR	p	No	AHR	p
Sex
Female	Low	54	1		66	1		16	1		63	1
Female	High	29	0.48	0.063^a	17	0.74	0.521^a	17	0.66	0.624^a	15	0.58	0.409^a
Male	Low	110	1		137	1		19	1		131	1
Male	High	73	1.50	0.076^a	46	1.80	0.018^a	25	3.30	0.136^a	44	1.77	0.057^a
Age
< = 60	Low	70	1		87	1		10	1		84	1
< = 60	High	43	1.12	0.713^a	26	1.45	0.266^a	15	494718.82	0.973^a	26	1.10	0.823^a
> 60	Low	94	1		116	1		25	1		110	1
> 60	High	59	1.08	0.770^a	37	1.29	0.379^a	27	1.05	0.931^a	33	1.67	0.150^a
Cell differentiation
Well	Low	25	1		30	1		8	1		30	1
Well	High	13	1.86	0.292^b	8	0.83	0.812^b	10	3.77	0.355^b	6	1.25	0.848^b
Moderate + Poor	Low	139	1		173	1		27	1		164	1
Moderate + Poor	High	89	1.04	0.864^b	55	1.42	0.114^b	32	1.44	0.522^b	53	1.45	0.180^b
N classification
N0	Low	67	1		85	1		26	1		82	1
N0	High	51	0.84	0.604^e	33	0.75	0.445^e	33	0.99	0.992^e	30	0.61	0.374^e
N1,N2,N3	Low	97	1		118	1		9	1		112	1
N1,N2,N3	High	51	1.20	0.459^e	30	2.00	0.009^e	9	3.48	0.309^e	29	1.88	0.041^e
T classification
T1 + T2	Low	73	1		85	1		34	1		83	1
T1 + T2	High	33	1.88	0.125^d	21	1.26	0.604^d	26	1.75	0.344^d	21	2.18	0.220^d
T3 + T4	Low	91	1		118	1		1	1		111	1
T3 + T4	High	69	0.91	0.678^d	42	1.41	0.173^d	16	0.29	0.458^d	38	1.26	0.438^d
AJCC pathological stage
I + II	Low	39	1		44	1		25	1		43	1
I + II	High	18	0.73	0.649^c	13	0.45	0.292^c	21	1.34	0.667^c	13	0.00	0.973^c
III + VI	Low	125	1		159	1		10	1		151	1
III + VI	High	84	1.16	0.460^c	50	1.63	0.030^c	21	2.28	0.339^c	46	1.65	0.066^c

OS overall survival, PFI progression-free interval survival, DFI disease-specific survival, DSS disease-specific survival, ROC receiver operating characteristic curve, AJCC American Joint Committee on Cancer, CI confidence interval, AHR adjusted hazard ratio
^aAdjusted for cell differentiation (moderate + poor vs. well) and AJCC pathological stage (stage III + IV vs stage I + II)
^bAdjusted for AJCC pathological stage (stage III + IV vs stage I + II)
^cAdjusted for cell differentiation (moderate + poor vs. well)
^dAdjusted for cell differentiation (moderate + poor vs. well) and N classification (N1, N2 vs N0)
^eAdjusted for cell differentiation (moderate + poor vs. well) and T classification (T3, T4 vs T1 + T2)

ISSN: 1475-2867